Welcome to LookChem.com Sign In|Join Free
  • or
2-Amino-2-methylpropanol-d6 is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

51805-95-9

Post Buying Request

51805-95-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

51805-95-9 Usage

Chemical Properties

Yellow-Orange Liquid

Check Digit Verification of cas no

The CAS Registry Mumber 51805-95-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,8,0 and 5 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 51805-95:
(7*5)+(6*1)+(5*8)+(4*0)+(3*5)+(2*9)+(1*5)=119
119 % 10 = 9
So 51805-95-9 is a valid CAS Registry Number.

51805-95-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-Amino-2-methylpropanol-d6

1.2 Other means of identification

Product number -
Other names 2-amino-3,3,3-trideuterio-2-(trideuteriomethyl)propan-1-ol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:51805-95-9 SDS

51805-95-9Downstream Products

51805-95-9Relevant academic research and scientific papers

2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES

-

Paragraph 0310; 0321-0322, (2020/10/20)

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein α, β, R2, R3, R4, R5, R8, R9, X1, X6, and X7 are defined in the specification. The compounds of formula 1 are receptor-interacting protein kinase 2 (RIPK2) inhibitors for treating e.g. type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer and non-malignant proliferative disorders, such as e.g. allergic rhinitis, asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, Sjogren's syndrome, ankylosing spondylitis, Behcet's disease, graft versus host disease, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction and thrombosis. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 107 to 208; examples 1 to 109; table 1). An exemplary compound is e.g. N-cyclopropyl-2-fluoro-5-(l-(2-fluoroethyl)-3-(l-hydroxy-2-methylpropan-2-yl)-2-oxo-2,3-dihydro-lH-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide (example 1).

Synthesis of deuterium-labeled hydroxybupropion

Li, Jian,Tian, Lei,Zhang, Chi,Chen, Liqin

, p. 411 - 413 (2015/09/15)

This paper describes the synthesis of deuterium-labeled hydroxybupropion. Mass spectrometry analysis of the compound revealed over 98% deuterium enrichment. This paper describes the synthesis of deuterium-labeled hydroxybupropion. Several different methods were applied to introduce deuterium, while Strecker reaction is the successful method to ensure deuterium enrichment. Mass spectrometry analysis of the product revealed over 98% of deuterium enrichment.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 51805-95-9